Stifel Nicolaus Has Lowered Expectations for OptimizeRx (NASDAQ:OPRX) Stock Price

Posted by George Bondi on Nov 12th, 2026

OptimizeRx (NASDAQ:OPRX – Get Free Report) had its price objective cut by Stifel Nicolaus from $12.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target indicates a potential upside of 22.91% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research note on Tuesday, October 27th. Citizens Jmp upped their price objective on OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Friday, August 14th. Weiss Ratings raised OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. B. Riley Financial raised their target price on OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Finally, UBS Group set a $11.00 price target on OptimizeRx in a research note on Friday, August 14th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.43.

Check Out Our Latest Stock Analysis on OPRX

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $8.95 on Thursday. The firm’s 50-day moving average price is $8.43 and its 200-day moving average price is $7.24. OptimizeRx has a 52-week low of $4.54 and a 52-week high of $16.37. The company has a market cap of $168.62 million, a PE ratio of 38.91 and a beta of 1.20. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14.

OptimizeRx (NASDAQ:OPRX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $21.19 million. As a group, analysts anticipate that OptimizeRx will post 0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OPRX. Royce & Associates LP boosted its holdings in OptimizeRx by 20.7% in the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock worth $10,981,000 after buying an additional 225,659 shares during the period. Rice Hall James & Associates LLC raised its holdings in OptimizeRx by 1.9% during the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock valued at $3,780,000 after acquiring an additional 11,247 shares during the period. Dimensional Fund Advisors LP raised its holdings in OptimizeRx by 22.3% during the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after acquiring an additional 102,661 shares during the period. AWM Investment Company Inc. bought a new stake in OptimizeRx during the second quarter valued at about $1,375,000. Finally, Renaissance Technologies LLC lifted its position in shares of OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock valued at $1,362,000 after acquiring an additional 187,278 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

(Get Free Report)

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.